{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:37:39Z","timestamp":1791632259475,"version":"4.3.4"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s11926-020-00953-0","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:02:25Z","timestamp":1600704145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches"],"prefix":"10.1007","volume":"22","author":[{"given":"Hanlin","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingran","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"10103","key":"953_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/s0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet (Lond, Engl). 2017;390(10103):1685\u201399. https:\/\/doi.org\/10.1016\/s0140-6736(17)30933-9.","journal-title":"Lancet (Lond, Engl)"},{"key":"953_CR2","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"953_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-019-0032-5","volume":"18","author":"CH Patel","year":"2019","unstructured":"Patel CH, Leone RD, Horton MR, Powell JD. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discov. 2019;18(9):669\u201388. https:\/\/doi.org\/10.1038\/s41573-019-0032-5.","journal-title":"Nat Rev Drug Discov"},{"key":"953_CR4","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.redox.2019.101122","volume":"25","author":"L Doridot","year":"2019","unstructured":"Doridot L, Jeljeli M, Ch\u00eane C, Batteux F. Implication of oxidative stress in the pathogenesis of systemic sclerosis via inflammation, autoimmunity and fibrosis. Redox Biol. 2019;25:101122. https:\/\/doi.org\/10.1016\/j.redox.2019.101122.","journal-title":"Redox Biol"},{"key":"953_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2018.04.554","volume":"125","author":"S Svegliati","year":"2018","unstructured":"Svegliati S, Spadoni T, Moroncini G, Gabrielli A. NADPH oxidase, oxidative stress and fibrosis in systemic sclerosis. Free Radic Biol Med. 2018;125:90\u20137. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.04.554.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"953_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1074\/jbc.M112.431973","volume":"288","author":"M Jain","year":"2013","unstructured":"Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, et al. Mitochondrial reactive oxygen species regulate transforming growth factor-\u03b2 signaling. J Biol Chem. 2013;288(2):770\u20137. https:\/\/doi.org\/10.1074\/jbc.M112.431973.","journal-title":"J Biol Chem"},{"issue":"341","key":"953_CR7","doi-asserted-by":"publisher","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","volume":"7","author":"S Svegliati","year":"2014","unstructured":"Svegliati S, Marrone G, Pezone A, Spadoni T, Grieco A, Moroncini G, et al. Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal. 2014;7(341):ra84. https:\/\/doi.org\/10.1126\/scisignal.2004592.","journal-title":"Sci Signal"},{"issue":"10","key":"953_CR8","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1172\/JCI94624","volume":"127","author":"Y Wei","year":"2017","unstructured":"Wei Y, Kim TJ, Peng DH, Duan D, Gibbons DL, Yamauchi M, et al. Fibroblast-specific inhibition of TGF-\u03b21 signaling attenuates lung and tumor fibrosis. J Clin Invest. 2017;127(10):3675\u201388. https:\/\/doi.org\/10.1172\/JCI94624.","journal-title":"J Clin Invest"},{"issue":"12","key":"953_CR9","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","volume":"82","author":"BN Singh","year":"2011","unstructured":"Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82(12):1807\u201321. https:\/\/doi.org\/10.1016\/j.bcp.2011.07.093.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"953_CR10","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1056\/NEJMc1915189","volume":"382","author":"HA Chapman","year":"2020","unstructured":"\u2022\u2022 Chapman HA, Wei Y, Montas G, Leong D, Golden JA, Trinh BN, et al. Reversal of TGF\u03b21-driven profibrotic state in patients with pulmonary fibrosis. N Engl J Med. 2020;382(11):1068\u201370. https:\/\/doi.org\/10.1056\/NEJMc1915189This study found EGCG was effective in ameliorating fibrosis in IPF patients.","journal-title":"N Engl J Med"},{"issue":"5","key":"953_CR11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.41163","volume":"72","author":"M Huang","year":"2020","unstructured":"Huang M, Cai G, Baugh LM, Liu Z, Smith A, Watson M, et al. Systemic sclerosis dermal fibroblasts induce cutaneous fibrosis through lysyl oxidase\u2013like 4: new evidence from three-dimensional skin-like tissues. Arthritis Rheumatol. 2020;72(5):791\u2013801. https:\/\/doi.org\/10.1002\/art.41163.","journal-title":"Arthritis Rheumatol"},{"key":"953_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41580-020-0230-3","volume":"21","author":"H Sies","year":"2020","unstructured":"Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21:363\u201383. https:\/\/doi.org\/10.1038\/s41580-020-0230-3.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"953_CR13","doi-asserted-by":"publisher","unstructured":"Kavian N, Mehlal S, Jeljeli M, Saidu NEB, Nicco C, Cerles O et al. The Nrf2-antioxidant response element signaling pathway controls fibrosis and autoimmunity in scleroderma. Front Immunol. 2018;9(AUG). https:\/\/doi.org\/10.3389\/fimmu.2018.01896","DOI":"10.3389\/fimmu.2018.01896"},{"key":"953_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.trsl.2016.12.002","volume":"183","author":"J Wei","year":"2017","unstructured":"Wei J, Zhu H, Lord G, Bhattachayya M, Jones BM, Allaway G, et al. Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative. Transl Res. 2017;183:71\u201386.e1. https:\/\/doi.org\/10.1016\/j.trsl.2016.12.002.","journal-title":"Transl Res"},{"key":"953_CR15","doi-asserted-by":"publisher","first-page":"113846","DOI":"10.1016\/j.bcp.2020.113846","volume":"174","author":"R Wu","year":"2020","unstructured":"Wu R, Zhang H, Zhao M, Li J, Hu Y, Fu J, et al. Nrf2 in keratinocytes protects against skin fibrosis via regulating epidermal lesion and inflammatory response. Biochem Pharmacol. 2020;174:113846. https:\/\/doi.org\/10.1016\/j.bcp.2020.113846.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"953_CR16","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.jid.2018.10.027","volume":"139","author":"LMB Perera","year":"2019","unstructured":"Perera LMB, Sekiguchi A, Uchiyama A, Uehara A, Fujiwara C, Yamazaki S, et al. The regulation of skin fibrosis in systemic sclerosis by extracellular ATP via P2Y2 purinergic receptor. J Investig Dermatol. 2019;139(4):890\u20139. https:\/\/doi.org\/10.1016\/j.jid.2018.10.027.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"953_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jdermsci.2019.08.004","volume":"96","author":"A Sekiguchi","year":"2019","unstructured":"Sekiguchi A, Motegi S-I, Fujiwara C, Yamazaki S, Inoue Y, Uchiyama A, et al. Inhibitory effect of kaempferol on skin fibrosis in systemic sclerosis by the suppression of oxidative stress. J Dermatol Sci. 2019;96(1):8\u201317. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.08.004.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"953_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrrheum.2016.223","volume":"13","author":"J Varga","year":"2017","unstructured":"Varga J, Marangoni RG. Dermal white adipose tissue implicated in SSc pathogenesis. Nat Rev Rheumatol. 2017;13(2):71\u20132. https:\/\/doi.org\/10.1038\/nrrheum.2016.223.","journal-title":"Nat Rev Rheumatol"},{"key":"953_CR19","doi-asserted-by":"publisher","first-page":"iii25","DOI":"10.1093\/rheumatology\/kez105.003","volume":"58","author":"E Derrett-Smith","year":"2019","unstructured":"Derrett-Smith E, Shi-Wen X, Abraham D, Lacombe O, Broqua P, Junien JL, et al. In vivo assessment of prevention of lung fibrosis using the pan-ppar agonist lanifibranor in the T\u03b2RII\u0394k-fib mouse model of systemic sclerosis. Rheumatology (United Kingdom). 2019;58:iii25. https:\/\/doi.org\/10.1093\/rheumatology\/kez105.003.","journal-title":"Rheumatology (United Kingdom)"},{"issue":"11","key":"953_CR20","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","volume":"76","author":"J Avouac","year":"2017","unstructured":"Avouac J, Konstantinova I, Guignabert C, Pezet S, Sadoine J, Guilbert T, et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017;76(11):1931\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210821.","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"953_CR21","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1111\/bph.14450","volume":"175","author":"C del Rio","year":"2018","unstructured":"del Rio C, Cantarero I, Palomares B, G\u00f3mez-Ca\u00f1as M, Fern\u00e1ndez-Ruiz J, Pavicic C, et al. VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation through PPAR\u03b3- and CB2 receptor-dependent pathways. Br J Pharmacol. 2018;175(19):3813\u201331. https:\/\/doi.org\/10.1111\/bph.14450.","journal-title":"Br J Pharmacol"},{"key":"953_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bcp.2019.02.029","volume":"163","author":"A Garc\u00eda-Mart\u00edn","year":"2019","unstructured":"Garc\u00eda-Mart\u00edn A, Garrido-Rodr\u00edguez M, Navarrete C, Caprioglio D, Palomares B, DeMesa J, et al. Cannabinoid derivatives acting as dual PPAR\u03b3\/CB2 agonists as therapeutic agents for systemic sclerosis. Biochem Pharmacol. 2019;163:321\u201334. https:\/\/doi.org\/10.1016\/j.bcp.2019.02.029.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"953_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12974-018-1103-y","volume":"15","author":"C Navarrete","year":"2018","unstructured":"Navarrete C, Carrillo-Salinas F, Palomares B, Mecha M, Jim\u00e9nez-Jim\u00e9nez C, Mestre L, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflamm. 2018;15(1):64. https:\/\/doi.org\/10.1186\/s12974-018-1103-y.","journal-title":"J Neuroinflamm"},{"key":"953_CR24","doi-asserted-by":"publisher","unstructured":"Korman B, Marangoni RG, Lord G, Olefsky J, Tourtellotte W, Varga J. Adipocyte-specific repression of PPAR-gamma by NCoR contributes to scleroderma skin fibrosis. Arthritis Res Ther. 2018;20(1). https:\/\/doi.org\/10.1186\/s13075-018-1630-z","DOI":"10.1186\/s13075-018-1630-z"},{"key":"953_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jpba.2018.09.021","volume":"162","author":"\u00c1 Fern\u00e1ndez-Ochoa","year":"2019","unstructured":"Fern\u00e1ndez-Ochoa \u00c1, Quirantes-Pin\u00e9 R, Borr\u00e1s-Linares I, Gemperline D, Alarc\u00f3n Riquelme ME, Beretta L, et al. Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients. J Pharm Biomed Anal. 2019;162:82\u201390. https:\/\/doi.org\/10.1016\/j.jpba.2018.09.021.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"953_CR26","doi-asserted-by":"publisher","first-page":"7626","DOI":"10.1038\/s41598-018-25992-7","volume":"8","author":"F Murgia","year":"2018","unstructured":"Murgia F, Svegliati S, Poddighe S, Lussu M, Manzin A, Spadoni T, et al. Metabolomic profile of systemic sclerosis patients. Sci Rep. 2018;8(1):7626. https:\/\/doi.org\/10.1038\/s41598-018-25992-7.","journal-title":"Sci Rep"},{"key":"953_CR27","doi-asserted-by":"publisher","unstructured":"Renaud L, da Silveira WA, Takamura N, Hardiman G, Feghali-Bostwick C. Prominence of IL6, IGF, TLR, and bioenergetics pathway perturbation in lung tissues of scleroderma patients with pulmonary fibrosis. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.00383.","DOI":"10.3389\/fimmu.2020.00383"},{"issue":"1","key":"953_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s42255-018-0008-5","volume":"1","author":"X Zhao","year":"2019","unstructured":"Zhao X, Psarianos P, Ghoraie LS, Yip K, Goldstein D, Gilbert R, et al. Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis. Nat Metabolism. 2019;1(1):147\u201357. https:\/\/doi.org\/10.1038\/s42255-018-0008-5.","journal-title":"Nat Metabolism"},{"issue":"13","key":"953_CR29","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.4161\/cc.10.13.16227","volume":"10","author":"R Castello-Cros","year":"2011","unstructured":"Castello-Cros R, Whitaker-Menezes D, Molchansky A, Purkins G, Soslowsky LJ, Beason DP, et al. Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis. Cell cycle (Georgetown, Tex). 2011;10(13):2140\u201350. https:\/\/doi.org\/10.4161\/cc.10.13.16227.","journal-title":"Cell cycle (Georgetown, Tex)"},{"issue":"8","key":"953_CR30","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1002\/1529-0131(200108)44:8<1865::Aid-art325>3.0.Co;2-m","volume":"44","author":"O Kowal-Bielecka","year":"2001","unstructured":"Kowal-Bielecka O, Distler O, Neidhart M, K\u00fcnzler P, Rethage J, Nawrath M, et al. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis. Arthritis Rheum. 2001;44(8):1865\u201375. https:\/\/doi.org\/10.1002\/1529-0131(200108)44:8<1865::Aid-art325>3.0.Co;2-m.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"953_CR31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/art.11042","volume":"48","author":"O Kowal-Bielecka","year":"2003","unstructured":"Kowal-Bielecka O, Distler O, Kowal K, Siergiejko Z, Chwie\u0107ko J, Sulik A, et al. Elevated levels of leukotriene B4 and leukotriene E4 in bronchoalveolar lavage fluid from patients with scleroderma lung disease. Arthritis Rheum. 2003;48(6):1639\u201346. https:\/\/doi.org\/10.1002\/art.11042.","journal-title":"Arthritis Rheum"},{"key":"953_CR32","doi-asserted-by":"publisher","unstructured":"\u2022 Liang M, Lv J, Jiang Z, He H, Chen C, Xiong Y et al. The leukotriene B4 -leukotriene B4 receptor 1 axis promotes myofibroblast differentiation and tissue fibrosis in systemic sclerosis. Arthritis Rheumatol (Hoboken, NJ). 2019. https:\/\/doi.org\/10.1002\/art.41192. This study found LTB4-BLT1 axis contributed to fibrosis in SSc.","DOI":"10.1002\/art.41192"},{"issue":"3","key":"953_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jaci.2019.11.032","volume":"145","author":"T B\u00e4rnthaler","year":"2020","unstructured":"\u2022 B\u00e4rnthaler T, Theiler A, Zabini D, Trautmann S, Stacher-Priehse E, Lanz I, et al. Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue. J Allergy Clin Immunol. 2020;145(3):818\u201333.e11. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.032This study found inhibition of 15-Prostaglandin dehydrogenase show anti-fibrotic effects.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"953_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10875-011-9601-z","volume":"32","author":"IH Bassyouni","year":"2012","unstructured":"Bassyouni IH, Talaat RM, Salem TA. Serum concentrations of cyclooxygenase-2 in patients with systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Clin Immunol. 2012;32(1):124\u201330. https:\/\/doi.org\/10.1007\/s10875-011-9601-z.","journal-title":"J Clin Immunol"},{"issue":"11","key":"953_CR35","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1096\/fj.201600646R","volume":"30","author":"RB Zurier","year":"2016","unstructured":"Zurier RB, Burstein SH. Cannabinoids, inflammation, and fibrosis. FASEB J. 2016;30(11):3682\u20139. https:\/\/doi.org\/10.1096\/fj.201600646R.","journal-title":"FASEB J"},{"key":"953_CR36","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V et al. Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis & Rheumatology. 2020;n\/a(n\/a). https:\/\/doi.org\/10.1002\/art.41294. This study led to the Phase III trial of lenabasum.","DOI":"10.1002\/art.41294"},{"key":"953_CR37","doi-asserted-by":"publisher","unstructured":"Hinchcliff M. Lenabasum for skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2020;n\/a(n\/a). doi:https:\/\/doi.org\/10.1002\/art.41302.","DOI":"10.1002\/art.41302"},{"issue":"1","key":"953_CR38","doi-asserted-by":"publisher","first-page":"111881","DOI":"10.1016\/j.yexcr.2020.111881","volume":"389","author":"T Ruhl","year":"2020","unstructured":"Ruhl T, Karthaus N, Kim B-S, Beier JP. The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs. Exp Cell Res. 2020;389(1):111881. https:\/\/doi.org\/10.1016\/j.yexcr.2020.111881.","journal-title":"Exp Cell Res"},{"issue":"3","key":"953_CR39","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jid.2019.07.719","volume":"140","author":"J Avouac","year":"2020","unstructured":"Avouac J, Pezet S, Gonzalez V, Baudoin L, Cauvet A, Ruiz B, et al. Estrogens counteract the profibrotic effects of TGF-\u03b2 and their inhibition exacerbates experimental dermal fibrosis. J Investig Dermatol. 2020;140(3):593\u2013601.e7. https:\/\/doi.org\/10.1016\/j.jid.2019.07.719.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"953_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jdermsci.2014.10.007","volume":"77","author":"L Zhu","year":"2015","unstructured":"Zhu L, Song Y, Li M. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation. J Dermatol Sci. 2015;77(1):63\u201370. https:\/\/doi.org\/10.1016\/j.jdermsci.2014.10.007.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"953_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/annrheumdis-2014-206386","volume":"75","author":"M Elhai","year":"2016","unstructured":"Elhai M, Avouac J, Walker UA, Matucci-Cerinic M, Riemekasten G, Air\u00f2 P, et al. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2016;75(1):163\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206386.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"953_CR42","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/art.27463","volume":"62","author":"S Bu","year":"2010","unstructured":"Bu S, Asano Y, Bujor A, Highland K, Hant F, Trojanowska M. Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum. 2010;62(7):2117\u201326. https:\/\/doi.org\/10.1002\/art.27463.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"953_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41598-018-37074-9","volume":"9","author":"M Kano","year":"2019","unstructured":"Kano M, Kobayashi T, Date M, Tennichi M, Hamaguchi Y, Strasser DS, et al. Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod. Sci Rep. 2019;9(1):658. https:\/\/doi.org\/10.1038\/s41598-018-37074-9.","journal-title":"Sci Rep"},{"key":"953_CR44","doi-asserted-by":"publisher","unstructured":"Cartier A, Hla T. Sphingosine 1-phosphate: lipid signaling in pathology and therapy. Science (New York, NY). 2019;366(6463). https:\/\/doi.org\/10.1126\/science.aar5551","DOI":"10.1126\/science.aar5551"},{"issue":"2","key":"953_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14728222.2020.1721468","volume":"24","author":"H Zou","year":"2020","unstructured":"Zou H, Zhu N, Li S. The emerging role of dipeptidyl-peptidase-4 as a therapeutic target in lung disease. Expert Opin Ther Targets. 2020;24(2):147\u201353. https:\/\/doi.org\/10.1080\/14728222.2020.1721468.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"953_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.41058","volume":"72","author":"A Soare","year":"2020","unstructured":"\u2022\u2022 Soare A, Gy\u00f6rfi HA, Matei AE, Dees C, Rauber S, Wohlfahrt T, et al. Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2020;72(1):137\u201349. https:\/\/doi.org\/10.1002\/art.41058This study showed repurposing of DPP-4 inhibitors to be a novel anti-fibrotic therapy.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"953_CR47","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41374-018-0080-1","volume":"98","author":"J Xu","year":"2018","unstructured":"Xu J, Wang J, He M, Han H, Xie W, Wang H, et al. Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension. Lab Invest. 2018;98(10):1333\u201346. https:\/\/doi.org\/10.1038\/s41374-018-0080-1.","journal-title":"Lab Invest"},{"key":"953_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.05.007","volume":"201","author":"M Anderluh","year":"2019","unstructured":"Anderluh M, Kocic G, Tomovic K, Kocic H, Smelcerovic A. DPP-4 inhibition: a novel therapeutic approach to the treatment of pulmonary hypertension? Pharmacol Ther. 2019;201:1\u20137. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.05.007.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"953_CR49","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41591-018-0087-6","volume":"24","author":"S Rangarajan","year":"2018","unstructured":"Rangarajan S, Bone NB, Zmijewska AA, Jiang S, Park DW, Bernard K, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24(8):1121\u20137. https:\/\/doi.org\/10.1038\/s41591-018-0087-6.","journal-title":"Nat Med"},{"issue":"1","key":"953_CR50","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/s41467-019-10839-0","volume":"10","author":"V Kheirollahi","year":"2019","unstructured":"\u2022\u2022 Kheirollahi V, Wasnick RM, Biasin V, Vazquez-Armendariz AI, Chu X, Moiseenko A, et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun. 2019;10(1):2987. https:\/\/doi.org\/10.1038\/s41467-019-10839-0This study found that metformin could induced lipogenic differentiation of myofiborblasts via BMP2 mediated- PPAR\u03b3 phosphorylation.","journal-title":"Nat Commun"},{"issue":"10","key":"953_CR51","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1002\/art.40554","volume":"70","author":"H Karmouty-Quintana","year":"2018","unstructured":"Karmouty-Quintana H, Molina JG, Philip K, Bellocchi C, Gudenkauf B, Wu M, et al. The antifibrotic effect of A2B adenosine receptor antagonism in a mouse model of dermal fibrosis. Arthritis Rheumatol. 2018;70(10):1673\u201384. https:\/\/doi.org\/10.1002\/art.40554.","journal-title":"Arthritis Rheumatol"},{"key":"953_CR52","doi-asserted-by":"publisher","unstructured":"\u2022 Zhang Y, Zhu H, Layritz F, Luo H, Wohlfahrt T, Chen CW et al. Recombinant adenosine deaminase ameliorates inflammation, vascular disease and fibrosis in preclinical models of systemic sclerosis. Arthritis Rheumatol. 2020. https:\/\/doi.org\/10.1002\/art.41259. This study found recombinant pegylated adenosine deaminase was able to mitigate inflammation, fibrosis and vasculopathy.","DOI":"10.1002\/art.41259"},{"issue":"10","key":"953_CR53","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1111\/exd.13730","volume":"27","author":"C Liu","year":"2018","unstructured":"Liu C, Yang X, Zhu P, Fujino M, Ito H, Takahashi K, et al. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease. Exp Dermatol. 2018;27(10):1104\u201311. https:\/\/doi.org\/10.1111\/exd.13730.","journal-title":"Exp Dermatol"},{"key":"953_CR54","doi-asserted-by":"publisher","unstructured":"\u2022 Skaug B, Khanna D, Swindell WR, Hinchcliff ME, Frech TM, Steen VD et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the Rheumatic Diseases. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215894. This study found innate and adaptive immune cell gene expression was more prominent in early diffuse SSc compared with later disease.","DOI":"10.1136\/annrheumdis-2019-215894"},{"issue":"5","key":"953_CR55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41584-019-0212-z","volume":"15","author":"G Kania","year":"2019","unstructured":"Kania G, Rudnik M, Distler O. Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis. Nat Rev Rheumatol. 2019;15(5):288\u2013302. https:\/\/doi.org\/10.1038\/s41584-019-0212-z.","journal-title":"Nat Rev Rheumatol"},{"key":"953_CR56","doi-asserted-by":"publisher","unstructured":"\u2022 Bhandari R, Ball MS, Martyanov V, Popovich D, Schaafsma E, Han S et al. Pro-fibrotic activation of human macrophages in systemic sclerosis Arthritis Rheumatol. 2020;n\/a(n\/a). https:\/\/doi.org\/10.1002\/art.41243. This study found that activation profile of SSc macrophages was pro-fibrotic.","DOI":"10.1002\/art.41243"},{"issue":"10","key":"953_CR57","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.jid.2019.04.006","volume":"139","author":"J Haub","year":"2019","unstructured":"\u2022 Haub J, Roehrig N, Uhrin P, Schabbauer G, Eulberg D, Melchior F, et al. Intervention of inflammatory monocyte activity limits dermal fibrosis. J Invest Dermatol. 2019;139(10):2144\u201353. https:\/\/doi.org\/10.1016\/j.jid.2019.04.006This study found that activation profile of SSc macrophages was pro-fibrotic.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"953_CR58","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nri3671","volume":"14","author":"F Ginhoux","year":"2014","unstructured":"Ginhoux F, Jung S. Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392\u2013404. https:\/\/doi.org\/10.1038\/nri3671.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"953_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-019-0025-4","volume":"18","author":"WJM Mulder","year":"2019","unstructured":"Mulder WJM, Ochando J, Joosten LAB, Fayad ZA, Netea MG. Therapeutic targeting of trained immunity. Nat Rev Drug Discov. 2019;18(7):553\u201366. https:\/\/doi.org\/10.1038\/s41573-019-0025-4.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"953_CR60","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1038\/s41467-019-13636-x","volume":"10","author":"M Jeljeli","year":"2019","unstructured":"\u2022 Jeljeli M, Riccio LGC, Doridot L, Ch\u00eane C, Nicco C, Chouzenoux S, et al. Trained immunity modulates inflammation-induced fibrosis. Nat Commun. 2019;10(1):5670. https:\/\/doi.org\/10.1038\/s41467-019-13636-xThis study highlighted trained immunity as a nascent treatment option for fibrosis.","journal-title":"Nat Commun"},{"key":"953_CR61","doi-asserted-by":"publisher","unstructured":"Kioon MDA, Tripodo C, Fernandez D, Kirou KA, Spiera RF, Crow MK et al. Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med. 2018;10(423). https:\/\/doi.org\/10.1126\/scitranslmed.aam8458.","DOI":"10.1126\/scitranslmed.aam8458"},{"key":"953_CR62","doi-asserted-by":"publisher","unstructured":"Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE et al. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight. 2018;3(9). https:\/\/doi.org\/10.1172\/jci.insight.98380","DOI":"10.1172\/jci.insight.98380"},{"issue":"9","key":"953_CR63","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/art.40163","volume":"69","author":"M Rossato","year":"2017","unstructured":"Rossato M, Affandi AJ, Thordardottir S, Wichers CGK, Cossu M, Broen JCA, et al. Association of MicroRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis. Arthritis Rheumatol. 2017;69(9):1891\u2013902. https:\/\/doi.org\/10.1002\/art.40163.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"953_CR64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4049\/jimmunol.1502190","volume":"197","author":"TA Delaney","year":"2016","unstructured":"Delaney TA, Morehouse C, Brohawn PZ, Groves C, Colonna M, Yao Y, et al. Type I IFNs regulate inflammation, vasculopathy, and fibrosis in chronic cutaneous graft-versus-host disease. J Immunol. 2016;197(1):42\u201350. https:\/\/doi.org\/10.4049\/jimmunol.1502190.","journal-title":"J Immunol"},{"key":"953_CR65","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jdermsci.2020.01.002","volume":"97","author":"S Miura","year":"2020","unstructured":"Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, et al. Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via retinoic acid-mediated regulatory T cell induction: a role in scleroderma. J Dermatol Sci. 2020;97:125\u201334. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.01.002.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"953_CR66","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/imr.12626","volume":"282","author":"P Bradding","year":"2018","unstructured":"Bradding P, Pejler G. The controversial role of mast cells in fibrosis. Immunol Rev. 2018;282(1):198\u2013231. https:\/\/doi.org\/10.1111\/imr.12626.","journal-title":"Immunol Rev"},{"issue":"9","key":"953_CR67","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1136\/annrheumdis-2011-200809","volume":"71","author":"T Hugle","year":"2012","unstructured":"Hugle T, White K, van Laar JM. Cell-to-cell contact of activated mast cells with fibroblasts and lymphocytes in systemic sclerosis. Ann Rheum Dis. 2012;71(9):1582. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200809.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"953_CR68","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/art.30190","volume":"63","author":"T Hugle","year":"2011","unstructured":"Hugle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor beta in systemic sclerosis. Arthritis Rheum. 2011;63(3):795\u20139. https:\/\/doi.org\/10.1002\/art.30190.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"953_CR69","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1172\/jci99088","volume":"128","author":"N Pincha","year":"2018","unstructured":"Pincha N, Hajam EY, Badarinath K, Batta SPR, Masudi T, Dey R, et al. PAI1 mediates fibroblast-mast cell interactions in skin fibrosis. J Clin Invest. 2018;128(5):1807\u201319. https:\/\/doi.org\/10.1172\/jci99088.","journal-title":"J Clin Invest"},{"issue":"5","key":"953_CR70","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/thoraxjnl-2018-211516","volume":"74","author":"C Shimbori","year":"2019","unstructured":"Shimbori C, Upagupta C, Bellaye P-S, Ayaub EA, Sato S, Yanagihara T, et al. Mechanical stress-induced mast cell degranulation activates TGF-\u03b21 signalling pathway in pulmonary fibrosis. Thorax. 2019;74(5):455\u201365. https:\/\/doi.org\/10.1136\/thoraxjnl-2018-211516.","journal-title":"Thorax."},{"issue":"2","key":"953_CR71","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/art.40701","volume":"71","author":"C Fujiwara","year":"2019","unstructured":"Fujiwara C, Uehara A, Sekiguchi A, Uchiyama A, Yamazaki S, Ogino S, et al. Suppressive regulation by MFG-E8 of latent transforming growth factor \u03b2\u2013induced fibrosis via binding to \u03b1v integrin: significance in the pathogenesis of fibrosis in systemic sclerosis. Arthritis Rheumatol. 2019;71(2):302\u201314. https:\/\/doi.org\/10.1002\/art.40701.","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"953_CR72","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/anie.201707948","volume":"57","author":"RJD Hatley","year":"2018","unstructured":"Hatley RJD, Macdonald SJF, Slack RJ, Le J, Ludbrook SB, Lukey PT. An \u03b1v-RGD integrin inhibitor toolbox: drug discovery insight, challenges and opportunities. Angew Chem (Int Ed Engl). 2018;57(13):3298\u2013321. https:\/\/doi.org\/10.1002\/anie.201707948.","journal-title":"Angew Chem (Int Ed Engl)"},{"key":"953_CR73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-immunol-041015-055402","volume":"34","author":"S Thiemann","year":"2016","unstructured":"Thiemann S, Baum LG. Galectins and immune responses-just how do they do those things they do? Annu Rev Immunol. 2016;34:243\u201364. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055402.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"953_CR74","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/j.jid.2017.04.035","volume":"137","author":"R Saigusa","year":"2017","unstructured":"Saigusa R, Asano Y, Nakamura K, Hirabayashi M, Miura S, Yamashita T, et al. Systemic sclerosis dermal fibroblasts suppress Th1 cytokine production via galectin-9 overproduction due to Fli1 deficiency. J Investig Dermatol. 2017;137(9):1850\u20139. https:\/\/doi.org\/10.1016\/j.jid.2017.04.035.","journal-title":"J Investig Dermatol"},{"issue":"1","key":"953_CR75","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12929-020-0616-8","volume":"27","author":"YA Hsu","year":"2020","unstructured":"Hsu YA, Chang CY, Lan JL, Li JP, Lin HJ, Chen CS, et al. Amelioration of bleomycin-induced pulmonary fibrosis via TGF-\u03b2-induced Smad and non-Smad signaling pathways in galectin-9-deficient mice and fibroblast cells. J Biomed Sci. 2020;27(1):24. https:\/\/doi.org\/10.1186\/s12929-020-0616-8.","journal-title":"J Biomed Sci"},{"issue":"12","key":"953_CR76","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1164\/rccm.201809-1737OC","volume":"199","author":"S Crnkovic","year":"2019","unstructured":"Crnkovic S, Egemnazarov B, Damico R, Marsh LM, Nagy BM, Douschan P, et al. Disconnect between fibrotic response and right ventricular dysfunction. Am J Respir Crit Care Med. 2019;199(12):1550\u201360. https:\/\/doi.org\/10.1164\/rccm.201809-1737OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"953_CR77","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1136\/annrheumdis-2019-215119","volume":"78","author":"A Mor","year":"2019","unstructured":"Mor A, Segal Salto M, Katav A, Barashi N, Edelshtein V, Manetti M, et al. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. Ann Rheum Dis. 2019;78(9):1260\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215119.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"953_CR78","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.41009","volume":"71","author":"VH Luong","year":"2019","unstructured":"Luong VH, Utsunomiya A, Chino T, Doanh LH, Matsushita T, Obara T, et al. Inhibition of the progression of skin inflammation, fibrosis, and vascular injury by blockade of the CX3CL1\/CX3CR1 pathway in experimental mouse models of systemic sclerosis. Arthritis Rheumatol. 2019;71(11):1923\u201334. https:\/\/doi.org\/10.1002\/art.41009.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"953_CR79","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jdermsci.2012.10.010","volume":"69","author":"M Arai","year":"2013","unstructured":"Arai M, Ikawa Y, Chujo S, Hamaguchi Y, Ishida W, Shirasaki F, et al. Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis. J Dermatol Sci. 2013;69(3):250\u20138. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.10.010.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"953_CR80","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41467-019-09683-z","volume":"10","author":"R Lande","year":"2019","unstructured":"\u2022 Lande R, Lee EY, Palazzo R, Marinari B, Pietraforte I, Santos GS, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-\u03b1 production in systemic sclerosis. Nat Commun. 2019;10(1):1731. https:\/\/doi.org\/10.1038\/s41467-019-09683-zThis study found that organize DNA into liquid-crystalline supramolecular complexes to enhance TLR9-mediated pDC secretion of interferon-\u03b1 in SSc.","journal-title":"Nat Commun"},{"key":"953_CR81","unstructured":"Khanna D BE, Nagaraja V, Koenig A, Khanna P, Young A, Moore J, Fox D, Lafyatis R. Tofacitinib in early diffuse cutaneous systemic sclerosis\u2014results of phase I\/II investigator-initiated, double-blind randomized placebo-controlled trial [abstract]. Arthritis Rheumatol 2019;71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/tofacitinib-in-early-diffuse-cutaneous-systemic-sclerosis-results-of-phase-i-ii-investigator-initiated-double-blind-randomized-placebo-controlled-trial\/ Accessed June 15, 2020."},{"key":"953_CR82","doi-asserted-by":"publisher","unstructured":"Xu D, Mu R, Wei X. The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol. 2019;10. https:\/\/doi.org\/10.3389\/fimmu.2019.02025.","DOI":"10.3389\/fimmu.2019.02025"},{"issue":"3","key":"953_CR83","doi-asserted-by":"publisher","first-page":"1900154","DOI":"10.1183\/13993003.00154-2019","volume":"54","author":"A Birnhuber","year":"2019","unstructured":"Birnhuber A, Crnkovic S, Biasin V, Marsh LM, Odler B, Sahu-Osen A, et al. IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. Eur Respir J. 2019;54(3):1900154. https:\/\/doi.org\/10.1183\/13993003.00154-2019.","journal-title":"Eur Respir J"},{"key":"953_CR84","first-page":"S146","volume":"36","author":"JC Mantero","year":"2018","unstructured":"Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, et al. Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I\/II biomarker trial. Clin Exp Rheumatol. 2018;36:S146\u2013S9.","journal-title":"Clin Exp Rheumatol"},{"key":"953_CR85","doi-asserted-by":"crossref","unstructured":"Allanore Y DC, Khanna D, Soubrane C, Esperet C, Marrache F, Bejuit R, Lahmar A, Wung P. Efficacy and safety of romilkimab in diffuse cutaneous systemic sclerosis (dcSSc): a randomized, double-blind, placebo-controlled, 24-week, proof of concept study [abstract]. Arthritis & rheumatology (Hoboken, NJ). 2019;71(suppl 10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-romilkimab-in-diffuse-cutaneous-systemic-sclerosis-dcssc-a-randomized-double-blind-placebo-controlled-24-week-proof-of-concept-study\/ Accessed June 15, 2020.","DOI":"10.1136\/annrheumdis-2020-eular.4830"},{"key":"953_CR86","unstructured":"Khanna D LC, Kuwana M, Allanore Y, Batalov A, Butrimiene I, Carreira P, Matucci Cerinic M, Distler O, Kaliterna DM, Mihai C, Mogensen M, Olesinska M, Pope JE, Riemekasten G, Rodriguez-Reyna TS, Santos MJ, van Laar J, Spotswood H, Siegel J, Jahreis A, Furst DE, Denton CP. Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]. Arthritis & rheumatology (Hoboken, NJ). 2018;70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-tocilizumab-for-the-treatment-of-systemic-sclerosis-results-from-a-phase-3-randomized-controlled-trial\/ Accessed June 15, 2020."},{"issue":"1","key":"953_CR87","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jid.2019.05.026","volume":"140","author":"AM Dufour","year":"2020","unstructured":"Dufour AM, Borowczyk-Michalowska J, Alvarez M, Truchetet ME, Modarressi A, Brembilla NC, et al. IL-17A dissociates inflammation from fibrogenesis in systemic sclerosis. J Invest Dermatol. 2020;140(1):103\u201312.e8. https:\/\/doi.org\/10.1016\/j.jid.2019.05.026.","journal-title":"J Invest Dermatol"},{"key":"953_CR88","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Maehara T, Kaneko N, Perugino CA, Mattoo H, Kers J, Allard-Chamard H et al. Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. The Journal of clinical investigation. 2020. https:\/\/doi.org\/10.1172\/JCI131700. This study demonstrated accumulation of CD4+ CTLs in the skin of SSc patients for the first time.","DOI":"10.1172\/JCI131700"},{"issue":"1","key":"953_CR89","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","volume":"72","author":"D Khanna","year":"2020","unstructured":"Khanna D, Spino C, Johnson S, Chung L, Whitfield ML, Denton CP, et al. Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial. Arthritis Rheumatol (Hoboken, NJ). 2020;72(1):125\u201336. https:\/\/doi.org\/10.1002\/art.41055.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"953_CR90","doi-asserted-by":"publisher","unstructured":"Taylor DK, Mittereder N, Kuta E, Delaney T, Burwell T, Dacosta K et al. T follicular helper-like cells contribute to skin fibrosis. Science Translational Medicine. 2018;10(431). https:\/\/doi.org\/10.1126\/scitranslmed.aaf5307","DOI":"10.1126\/scitranslmed.aaf5307"},{"issue":"4","key":"953_CR91","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","volume":"78","author":"L Ricard","year":"2019","unstructured":"Ricard L, Jachiet V, Malard F, Ye Y, Stocker N, Rivi\u00e8re S, et al. Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis. 2019;78(4):539\u201350. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214382.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"953_CR92","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, Kobayashi T, Mizumaki K, Kano M, Sawada T, Tennichi M, et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv. 2018;4(7):eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944.","journal-title":"Sci Adv"},{"issue":"2","key":"953_CR93","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol (Hoboken, NJ). 2018;70(2):308\u201316. https:\/\/doi.org\/10.1002\/art.40358.","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"953_CR94","doi-asserted-by":"publisher","first-page":"106389","DOI":"10.1016\/j.intimp.2020.106389","volume":"83","author":"R Tang","year":"2020","unstructured":"Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, et al. Safety and efficacy of rituximab in systemic sclerosis: a systematic review and meta-analysis. Int Immunopharmacol. 2020;83:106389. https:\/\/doi.org\/10.1016\/j.intimp.2020.106389.","journal-title":"Int Immunopharmacol"},{"key":"953_CR95","doi-asserted-by":"publisher","unstructured":"Tsou PS. Epigenetic control of scleroderma: current knowledge and future perspectives. Curr Rheumatol Rep. 2019;21(12). https:\/\/doi.org\/10.1007\/s11926-019-0877-y.","DOI":"10.1007\/s11926-019-0877-y"},{"issue":"5","key":"953_CR96","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molmed.2019.02.001","volume":"25","author":"J Henderson","year":"2019","unstructured":"Henderson J, Distler J, O'Reilly S. The role of epigenetic modifications in systemic sclerosis: a Druggable target. Trends Mol Med. 2019;25(5):395\u2013411. https:\/\/doi.org\/10.1016\/j.molmed.2019.02.001.","journal-title":"Trends Mol Med"},{"issue":"11","key":"953_CR97","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41584-018-0099-0","volume":"14","author":"C Angiolilli","year":"2018","unstructured":"Angiolilli C, Marut W, van der Kroef M, Chouri E, Reedquist KA, Radstake T. New insights into the genetics and epigenetics of systemic sclerosis. Nat Rev Rheumatol. 2018;14(11):657\u201373. https:\/\/doi.org\/10.1038\/s41584-018-0099-0.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"953_CR98","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1136\/annrheumdis-2018-213022","volume":"77","author":"Y He","year":"2018","unstructured":"He Y, Tsou P-S, Khanna D, Sawalha AH. Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. Ann Rheum Dis. 2018;77(8):1208\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213022.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"953_CR99","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2017-212265","volume":"77","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, P\u00f6tter S, Chen C-W, Liang R, Gelse K, Ludolph I, et al. Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis. 2018;77(5):744\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212265.","journal-title":"Ann Rheum Dis"},{"key":"953_CR100","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Dees C, P\u00f6tter S, Zhang Y, Bergmann C, Zhou X, Luber M et al. TGF\u03b2-induced epigenetic deregulation of SOCS3 facilitates STAT3-signaling to promote fibrosis. J Clin Invest. 2020. https:\/\/doi.org\/10.1172\/JCI122462. This study found that SOCS3 was a negative regulator of TGF\u03b2\u2013STAT3 signaling.","DOI":"10.1172\/JCI122462"},{"issue":"7744","key":"953_CR101","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/s41586-019-0896-x","volume":"566","author":"T Wohlfahrt","year":"2019","unstructured":"\u2022 Wohlfahrt T, Rauber S, Uebe S, Luber M, Soare A, Ekici A, et al. PU.1 controls fibroblast polarization and tissue fibrosis. Nature. 2019;566(7744):344\u20139. https:\/\/doi.org\/10.1038\/s41586-019-0896-xThis study found PU.1 could control fibroblast fate and function.","journal-title":"Nature"},{"issue":"1","key":"953_CR102","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2017-211501","volume":"77","author":"C Bergmann","year":"2018","unstructured":"Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, et al. The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. Ann Rheum Dis. 2018;77(1):150\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211501.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"953_CR103","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1073\/pnas.1813006116","volume":"116","author":"P-S Tsou","year":"2019","unstructured":"Tsou P-S, Campbell P, Amin MA, Coit P, Miller S, Fox DA, et al. Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. Proc Natl Acad Sci. 2019;116(9):3695\u2013702. https:\/\/doi.org\/10.1073\/pnas.1813006116.","journal-title":"Proc Natl Acad Sci"},{"key":"953_CR104","doi-asserted-by":"publisher","unstructured":"\u2022 Shin JY, Beckett JD, Bagirzadeh R, Creamer TJ, Shah AA, McMahan, Z et al. Epigenetic activation and memory at a TGFB2 enhancer in systemic sclerosis. Sci Transl Med. 2019;11(497). https:\/\/doi.org\/10.1126\/scitranslmed.aaw0790. This study found that TGF\u03b22 signaling might be a potentially targetable mechanism of fibrosis.","DOI":"10.1126\/scitranslmed.aaw0790"},{"issue":"12","key":"953_CR105","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/art.41041","volume":"71","author":"A Kozlova","year":"2019","unstructured":"Kozlova A, Pachera E, Maurer B, J\u00fcngel A, Distler JHW, Kania G, et al. Regulation of fibroblast apoptosis and proliferation by MicroRNA-125b in systemic sclerosis. Arthritis Rheumatol. 2019;71(12):2068\u201380. https:\/\/doi.org\/10.1002\/art.41041.","journal-title":"Arthritis Rheumatol"},{"key":"953_CR106","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jaut.2017.12.015","volume":"89","author":"E Chouri","year":"2018","unstructured":"Chouri E, Servaas NH, Bekker CPJ, Affandi AJ, Cossu M, Hillen MR, et al. Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J Autoimmun. 2018;89:162\u201370. https:\/\/doi.org\/10.1016\/j.jaut.2017.12.015.","journal-title":"J Autoimmun"},{"key":"953_CR107","doi-asserted-by":"publisher","unstructured":"Takata M, Pachera E, Frank-Bertoncelj M, Kozlova A, J\u00fcngel A, Whitfield ML et al. OTUD6B-AS1 might be a novel regulator of apoptosis in systemic sclerosis. Front Immunol. 2019;10(1100). https:\/\/doi.org\/10.3389\/fimmu.2019.01100.","DOI":"10.3389\/fimmu.2019.01100"},{"key":"953_CR108","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/annrheumdis-2019-216542","volume":"79","author":"CW Wasson","year":"2020","unstructured":"Wasson CW, Abignano G, Hermes H, Malaab M, Ross RL, Jimenez SA, et al. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann Rheum Dis. 2020;79:507\u201317. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216542.","journal-title":"Ann Rheum Dis"},{"key":"953_CR109","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Weng T, Huang J, Wagner EJ, Ko J, Wu M, Wareing NE et al. Downregulation of CFIm25 amplifies dermal fibrosis through alternative polyadenylation. J Exp Med. 2020;217(2). https:\/\/doi.org\/10.1084\/jem.20181384. This study highlighted alternative polyadenylation (APA) regulation as an important mechanism in SSc.","DOI":"10.1084\/jem.20181384"},{"issue":"8","key":"953_CR110","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1136\/annrheumdis-2014-205303","volume":"74","author":"N Altorok","year":"2015","unstructured":"Altorok N, Tsou P-S, Coit P, Khanna D, Sawalha AH. Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. Ann Rheum Dis. 2015;74(8):1612\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205303.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"953_CR111","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jid.2017.12.003","volume":"138","author":"W Ding","year":"2018","unstructured":"Ding W, Pu W, Wang L, Jiang S, Zhou X, Tu W, et al. Genome-wide DNA methylation analysis in systemic sclerosis reveals hypomethylation of IFN-associated genes in CD4+ and CD8+ T cells. J Investig Dermatol. 2018;138(5):1069\u201377. https:\/\/doi.org\/10.1016\/j.jid.2017.12.003.","journal-title":"J Investig Dermatol"},{"issue":"11","key":"953_CR112","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.autrev.2019.102396","volume":"18","author":"TW Henry","year":"2019","unstructured":"Henry TW, Mendoza FA, Jimenez SA. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy. Autoimmun Rev. 2019;18(11):102396. https:\/\/doi.org\/10.1016\/j.autrev.2019.102396.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"953_CR113","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.jid.2019.02.020","volume":"139","author":"S Arndt","year":"2019","unstructured":"Arndt S, Karrer S, Hellerbrand C, Bosserhoff AK. Bone morphogenetic protein-6 inhibits fibrogenesis in scleroderma offering treatment options for fibrotic skin disease. J Invest Dermatol. 2019;139(9):1914\u201324.e6. https:\/\/doi.org\/10.1016\/j.jid.2019.02.020.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"953_CR114","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, et al. Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 2012;64(8):2734\u201345. https:\/\/doi.org\/10.1002\/art.34424.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"953_CR115","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","volume":"72","author":"C Beyer","year":"2013","unstructured":"Beyer C, Reichert H, Akan H, Mallano T, Schramm A, Dees C, et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann Rheum Dis. 2013;72(7):1255\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202544.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"953_CR116","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","volume":"137","author":"R Lafyatis","year":"2017","unstructured":"Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, et al. Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82. J Investig Dermatol. 2017;137(12):2473\u201383. https:\/\/doi.org\/10.1016\/j.jid.2017.06.032.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"953_CR117","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1002\/art.34444","volume":"64","author":"A Horn","year":"2012","unstructured":"Horn A, Palumbo K, Cordazzo C, Dees C, Akhmetshina A, Tomcik M, et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 2012;64(8):2724\u201333. https:\/\/doi.org\/10.1002\/art.34444.","journal-title":"Arthritis Rheum"},{"issue":"14","key":"953_CR118","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-2012-01-403428","volume":"120","author":"P Zerr","year":"2012","unstructured":"Zerr P, Palumbo-Zerr K, Distler A, Tomcik M, Vollath S, Munoz LE, et al. Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease. Blood. 2012;120(14):2909\u201317. https:\/\/doi.org\/10.1182\/blood-2012-01-403428.","journal-title":"Blood."},{"issue":"5","key":"953_CR119","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1136\/annrheumdis-2011-200883","volume":"71","author":"A Horn","year":"2012","unstructured":"Horn A, Kireva T, Palumbo-Zerr K, Dees C, Tomcik M, Cordazzo C, et al. Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of established fibrosis. Ann Rheum Dis. 2012;71(5):785\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200883.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"953_CR120","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1136\/annrheumdis-2019-215066","volume":"78","author":"R Liang","year":"2019","unstructured":"Liang R, Kagwiria R, Zehender A, Dees C, Bergmann C, Ramming A, et al. Acyltransferase skinny hedgehog regulates TGF\u03b2-dependent fibroblast activation in SSc. Ann Rheum Dis. 2019;78(9):1269\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215066.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"953_CR121","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1756-185X.13247","volume":"21","author":"H Xiao","year":"2018","unstructured":"Xiao H, Zhang GF, Liao XP, Li XJ, Zhang J, Lin H, et al. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018;21(2):477\u201386. https:\/\/doi.org\/10.1111\/1756-185X.13247.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"953_CR122","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/s41467-019-09101-4","volume":"10","author":"JS Park","year":"2019","unstructured":"\u2022\u2022 Park JS, Oh Y, Park YJ, Park O, Yang H, Slania S, et al. Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma. Nat Commun. 2019;10(1):1128. https:\/\/doi.org\/10.1038\/s41467-019-09101-4This study demonstrated that TLY012 could bind death receptor 5 on myofibroblasts and arrest scleroderma.","journal-title":"Nat Commun"},{"issue":"1","key":"953_CR123","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41467-020-15647-5","volume":"11","author":"T Tsukui","year":"2020","unstructured":"\u2022\u2022 Tsukui T, Sun K-H, Wetter JB, Wilson-Kanamori JR, Hazelwood LA, Henderson NC, et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun. 2020;11(1):1920. https:\/\/doi.org\/10.1038\/s41467-020-15647-5This study built an atlas of collagen-producing cells and identified Cthrc1+ fibroblasts as drivers of fibrosis in SSc-ILD with single-cell RNA-sequencing.","journal-title":"Nat Commun"},{"issue":"10","key":"953_CR124","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","volume":"78","author":"E Valenzi","year":"2019","unstructured":"Valenzi E, Bulik M, Tabib T, Morse C, Sembrat J, Trejo Bittar H, et al. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease. Ann Rheum Dis. 2019;78(10):1379\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214865.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"953_CR125","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/annrheumdis-2019-216108","volume":"78","author":"A-E Matei","year":"2019","unstructured":"\u2022\u2022 Matei A-E, Chen C-W, Kiesewetter L, Gy\u00f6rfi A-H, Li Y-N, Trinh-Minh T, et al. Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Ann Rheum Dis. 2019;78(12):1686\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216108This study described vascularised skin equivalents as as a platform for evaluation of antifibrotic drugs.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-020-00953-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-020-00953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T20:19:56Z","timestamp":1632169196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-020-00953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":125,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["953"],"URL":"https:\/\/doi.org\/10.1007\/s11926-020-00953-0","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]},"assertion":[{"value":"4 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest. Figure  was created with .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"77"}}